Results 91 to 100 of about 4,889,797 (259)
A sustainable business ecosystem: a case study demonstrating biochar's potential
Biofuels, Bioproducts and Biorefining, EarlyView.Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola +4 more
wiley +1 more source
, 2010 This paper provides an analysis of the Tribunal’s jurisprudence for the period is provided in an introductory chapter “Developments in the Jurisprudence of the International Monetary Fund Administrative Tribunal: 2006.” In deciding on an application, the
International Monetary Fund
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
The Kallikrates vs the Kapodistrias Reforms in Greece: A Story of Moderate Success
Politics in Central Europe, 2018 This article aims to analyse and evaluate the implementation of Greek local government reforms based on the surrounding economic and political situation.
Kalimeri Vasiliki
doaj +1 more source
A European Deposit Insurance and Resolution Fund. CEPS Working Document No. 364, 10 May 2012 [PDF]
, 2012 The eurozone is caught in a ‘diabolical loop’ in which weak domestic banking systems damage sovereign fiscal positions and conversely, in which risky sovereign positions disproportionately threaten domestic banking stability.
Schoenmaker, Dirk, Gros, Daniel
core
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Economic Evolution in Euro-Adopting States vs. Future Adopters: A Comparative Analysis
EconomiesThis paper analyzes the macroeconomic evolution of the European Union member states that have adopted the Euro, compared to those that continue to use national currencies, with a specific focus on the Central and Eastern European countries during the ...
Nicoleta Georgeta Panait +1 more
doaj +1 more source
Measurement of Fiscal Council Independence in the Countries of the European Union
Problemy Zarządzania, 2016 Recent years have noted a strengthening of institutional solutions serving the improvement of budgetary standing in many countries. One such solution is the functioning of independent fiscal institutions, also known as fiscal councils.
Sławomir Franek
doaj +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source